Epidemiology, natural history, and risk factors of hepatocellular carcinoma;Épidémiologie, histoire naturelle, et facteurs de risque du carcinome hépatocellulaire

Revue du Praticien

Volumn 63, Issue 2, 2013, Pages

  Fares, Nadim ^a   Péron, Jean Marie ^a  

^a CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

SORAFENIB;

ADVANCED CANCER; ALCOHOL CONSUMPTION; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER SCREENING; CHEMOEMBOLIZATION; DEVELOPED COUNTRY; DISEASE ASSOCIATION; EPIDEMIC; HEPATITIS B; HEPATITIS C; HIGH RISK PATIENT; HISTORY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; NONALCOHOLIC FATTY LIVER; PRECANCER; RADIOFREQUENCY ABLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; DISEASE COURSE; FRANCE; HEALTH; LIVER TUMOR; PATHOLOGY; STATISTICS; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FRANCE; HUMANS; LIVER NEOPLASMS; RISK FACTORS; TREATMENT OUTCOME; WORLD HEALTH;

MLCS; MLOWN;

EID: 84875031089     PISSN: 00352640     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Borie F, Trétarre B, Bouvier AM, et al. Primitive liver cancers. epidemiology and geographical study in France. Eur J Gastroenterol Hepatol 2009;21:984-9.
2. Belot A, Grosclaude P, Bossard N, et al. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidémiol Santé Publique 2008;56:159-75
3. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis incidence and risk factors. Gastroenterology 2004;127:S35-50. (Pubitemid 39423368)
4. Rosa I, Denis J, Renard P, et al. Étude longitudinale descriptive de la prise en charge des CHC en France CHANGH Résultats préliminaires (résumé). JFHOD 2010:http://www.snfge.org/01- Bibliotheque/00A-Resumes-JFPD/2010/4247.html.
5. Donato F, Tagger A, Gelatti U, et al. Alcohol and hepatocellular carcinoma. the effect of lifetime intake and hepatitis virus infections in men and women Am J Epidemiol 2002, 15, 155:323-31. (Pubitemid 34132050)
6. Chen CJ. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
7. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31.
8. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27:1394-402. (Pubitemid 28228735)
9. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of alcohol on the progression of hepatitis C virus infection: meta-analysis. Clin Gastroenterol Hepatol 2005;3:1150-9. (Pubitemid 41565383)
10. Moriya K, Fujie H, Shintani Y, Yotsuyanagi H, Tsutsumi T, Ishibashi K, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice Nat Med 1998;4:1065-7. (Pubitemid 28417341)
11. Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91.
12. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults N Engl J Med 2003;348:1625-38 (Pubitemid 36459468)
13. N'Kontchou G, Paries J, Htar MT, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006;4:1062-8 (Pubitemid 44137435)
14. Ertle J, Dechene A, Sowa JP, et al. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011;128:2436-43.
15. Chuang SC, Lee YC, Hashibe M, Dai M, Zheng T, Boffetta P. Interaction between cigarette smoking and hepatitis B and C virus infection on the risk of liver cancer: a metaanalysis. Cancer Epidemiol Biomarkers Prev 2010;19:1261-8.
16. Zucman-Rossi J, Jeannot E, Nhieu JT, et al. Genotype phenotype correlation in hepatocellular adenoma newclassification and relationship with HCC. Hepatology 2006;43:515-24.
17. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-2.
18. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
19. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.